Diabetes News and Research

Latest Diabetes News and Research

National Minority Quality Forum launches novel resource to map lung cancer prevalence estimates

In recognition of World Cancer Day, the National Minority Quality Forum today launched the Lung Cancer Atlas. This novel resource enables users to map lung cancer prevalence estimates and total counts at the zip-code level for the United States as well as for individual states, federal and state legislative districts.

5 Feb 2011

First mobile application is now available for clinicians to diagnose bleeding disorders

Novo Nordisk announced today the availability of Coags Uncomplicated – the first mobile application to assist in the diagnosis of bleeding disorders – created in partnership with Craig Kessler, MD, Professor of Medicine and Pathology and Director of the Coagulation Laboratory, Georgetown University Hospital, Lombardi Comprehensive Cancer Center.

5 Feb 2011

ECR launches sleep aid product, Zolpimist Oral Spray in the US

NovaDel Pharma Inc. today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc.. ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

ECR announces availability of Zolpimist Oral Spray in the U.S.

ECR Pharmaceuticals Co., Inc., a subsidiary of Hi-Tech Pharmacal Co., Inc. announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

Salk Institute receives $2.3 million CIRM grant for translational research on Parkinson's disease

The Salk Institute has been awarded a $2.3 million grant by the California Institute for Regenerative Medicine for translational research focusing on developing a novel stem cell based therapy for Parkinson's disease.

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Queen’s scientist awarded Royal Society Wolfson Research Merit Award

One of Northern Ireland's leading scientists has received a top UK award, to support ground-breaking research into vascular stem cells and eye disease at Queen's University.

4 Feb 2011

Most Canadians want to do more to support cancer research

When it comes to cancer research, Canadians want to do more. A national survey released today in advance of World Cancer Day shows that more than half of Canadians 35 to 69 years of age feel cancer should be a top priority for health research. However, the survey also shows that a similar number do not know how to get involved in a way that could be helpful to other people.

4 Feb 2011

American Cancer Society report released on World Cancer Day

A new American Cancer Society report says cancers associated with lifestyles and behaviors related to economic development, including lung, breast, and colorectal cancers, will continue to rise in developing countries if preventive measures are not widely applied. The finding comes from the second edition of Global Cancer Facts & Figures and its academic publication, Global Cancer Statistics, published in CA: A Cancer Journal for Clinicians.

4 Feb 2011

Rolling back Clean Air Act has life and death stakes

The Trust for America's Health warns that Chairman Fred Upton's (R-MI) draft bill could undermine the Clean Air Act and thereby harm millions of Americans.

4 Feb 2011

Researchers identify regulatory defect that drives lupus

Researchers at Dana-Farber Cancer Institute in Cambridge, Mass., in collaboration with Jackson Laboratory scientists, have identified a regulatory defect that drives lupus.

4 Feb 2011

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors by the U.S. Food and Drug Administration.

4 Feb 2011

Kaiser Permanente receives $3 million CDC grant to continue SEARCH study for childhood diabetes

The Kaiser Permanente Southern California Department of Research & Evaluation has been awarded more than $3 million from the Centers for Disease Control and Prevention to continue the SEARCH for Diabetes in Youth Study for an additional five years to 2015.

4 Feb 2011

New way to stabilize proteins

A team of scientists at The Scripps Research Institute has discovered a new way to stabilize proteins — the workhorse biological macromolecules found in all organisms. Proteins serve as the functional basis of many types of biologic drugs used to treat everything from arthritis, anemia, and diabetes to cancer.

4 Feb 2011

CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds

CardioVascular BioTherapeutics, Inc. today announced it has submitted an application to the U.S. FDA to obtain "fast track" designation for CVBT-141B, its biological therapy to treat ischemic diabetic wounds based on the active ingredient fibroblast growth factor-1 (FGF-1).

4 Feb 2011

MedAssurant, UNC to assess relationship between insulin and cancer development

MedAssurant, a leading provider of data-driven healthcare solutions, today announced the initiation of a joint study with the University of North Carolina to assess the relationship between the use of long-acting insulin to treat diabetes and the development of cancer.

4 Feb 2011

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

4 Feb 2011

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported results through month 36 of the completed FAME™ Study.

4 Feb 2011

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN for the treatment of Diabetic Macular Edema, today announced month 36, top-line readout results for the FAME Study prepared by its licensee, Alimera Sciences.

4 Feb 2011

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.

3 Feb 2011